N
10.98
0.29 (2.71%)
| Penutupan Terdahulu | 10.69 |
| Buka | 10.70 |
| Jumlah Dagangan | 2,138,443 |
| Purata Dagangan (3B) | 5,022,901 |
| Modal Pasaran | 1,789,020,544 |
| Harga / Pendapatan (P/E TTM) | 4.26 |
| Harga / Jualan (P/S) | 1.65 |
| Harga / Buku (P/B) | 33.20 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | 38.14% |
| Margin Operasi (TTM) | 77.40% |
| EPS Cair (TTM) | 2.75 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 610.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 179.90% |
| Nisbah Semasa (MRQ) | 2.06 |
| Aliran Tunai Operasi (OCF TTM) | -189.21 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 61.88 M |
| Pulangan Atas Aset (ROA TTM) | 19.97% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Novavax, Inc. | Menaik | Menurun |
AISkor Stockmoo
-0.1
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -5.0 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -0.10 |
|
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 8.78% |
| % Dimiliki oleh Institusi | 57.19% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Shah Capital Management | 31 Dec 2025 | 14,558,780 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 19.00 (BTIG, 73.04%) | Beli |
| Median | 17.50 (59.38%) | |
| Rendah | 16.00 (HC Wainwright & Co., 45.72%) | Beli |
| Purata | 17.50 (59.38%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 9.17 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 Feb 2026 | 16.00 (45.72%) | Beli | 10.14 |
| BTIG | 20 Jan 2026 | 19.00 (73.04%) | Beli | 8.20 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CASEY MARK J | - | 9.82 | -12,592 | -120,287 |
| DRAGHIA-AKLI RUXANDRA | - | 9.49 | -11,313 | -107,360 |
| JACOBS JOHN C | - | 9.82 | -107,738 | -1,047,426 |
| KELLY JAMES PATRICK | - | 9.87 | -55,120 | -544,420 |
| O'HARA ELAINE | - | 9.82 | -38,773 | -378,579 |
| Jumlah Keseluruhan Kuantiti Bersih | -225,536 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -2,198,073 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 9.80 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| KELLY JAMES PATRICK | Pegawai | 07 Mar 2026 | Dibuang (-) | 5,904 | 9.98 | 58,922 |
| KELLY JAMES PATRICK | Pegawai | 07 Mar 2026 | Pelaksanaan pilihan | 12,223 | - | - |
| DRAGHIA-AKLI RUXANDRA | Pegawai | 03 Mar 2026 | Dibuang (-) | 11,313 | 9.49 | 107,360 |
| DRAGHIA-AKLI RUXANDRA | Pegawai | 03 Mar 2026 | Pelaksanaan pilihan | 26,667 | - | - |
| CASEY MARK J | Pegawai | 03 Mar 2026 | Dibuang (-) | 11,378 | 9.49 | 107,977 |
| CASEY MARK J | Pegawai | 03 Mar 2026 | Pelaksanaan pilihan | 37,500 | - | - |
| O'HARA ELAINE | Pegawai | 03 Mar 2026 | Dibuang (-) | 22,429 | 9.49 | 212,851 |
| O'HARA ELAINE | Pegawai | 03 Mar 2026 | Pelaksanaan pilihan | 56,334 | - | - |
| KELLY JAMES PATRICK | Pegawai | 03 Mar 2026 | Dibuang (-) | 20,850 | 9.49 | 197,867 |
| KELLY JAMES PATRICK | Pegawai | 03 Mar 2026 | Pelaksanaan pilihan | 43,167 | - | - |
| JACOBS JOHN C | Pegawai | 03 Mar 2026 | Dibuang (-) | 69,288 | 9.49 | 657,543 |
| JACOBS JOHN C | Pegawai | 03 Mar 2026 | Pelaksanaan pilihan | 150,167 | - | - |
| CASEY MARK J | Pegawai | 01 Mar 2026 | Dibuang (-) | 1,214 | 10.14 | 12,310 |
| CASEY MARK J | Pegawai | 01 Mar 2026 | Pelaksanaan pilihan | 4,000 | - | - |
| O'HARA ELAINE | Pegawai | 01 Mar 2026 | Dibuang (-) | 16,344 | 10.14 | 165,728 |
| O'HARA ELAINE | Pegawai | 01 Mar 2026 | Pelaksanaan pilihan | 59,600 | - | - |
| KELLY JAMES PATRICK | Pegawai | 01 Mar 2026 | Dibuang (-) | 28,366 | 10.14 | 287,631 |
| KELLY JAMES PATRICK | Pegawai | 01 Mar 2026 | Pelaksanaan pilihan | 58,666 | - | - |
| JACOBS JOHN C | Pegawai | 01 Mar 2026 | Dibuang (-) | 38,450 | 10.14 | 389,883 |
| JACOBS JOHN C | Pegawai | 01 Mar 2026 | Pelaksanaan pilihan | 83,333 | - | - |
| Papar semua | ||||||
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Jan 2026 | Pengumuman | Novavax Announces Entering into a License Agreement with Pfizer |
| 07 Jan 2026 | Pengumuman | Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |